Nitazene Control Act

Bill Number: H.R. 5032
Origin Chamber: House
Congress: 119th Congress, Session 1
Policy Area: Crime and Law Enforcement
Status: Introduced
Latest Action: 2025-08-22: Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Last Updated: 2026-07-01T08:09:08Z

AI-Generated Summary

Purpose of the Legislation

The Nitazene Control Act (H.R. 5032) aims to protect public health by permanently classifying a group of highly potent synthetic opioids known as nitazenes (benzimidazole-opioids) under Schedule I of the Controlled Substances Act (CSA). This scheduling treats them as drugs with high potential for abuse and no accepted medical use, making their manufacture, distribution, and possession illegal except under strict controls. The goal is to address their role in the illicit drug market and prevent overdose deaths by covering current and future variants of these substances.

Key Provisions

Class-Wide Scheduling: Adds nitazenes to Schedule I of the CSA, defining them chemically as substances with a benzimidazole core (a specific molecular structure), a benzyl group at one position, a nitrogen-containing side chain at another, and activity at the mu-opioid receptor (the brain's main pain-relief site targeted by opioids). Includes examples like etonitazene, clonitazene, and protonitazene, plus their salts, isomers, and similar compounds.
Transition from Temporary Scheduling: Any nitazenes previously placed on a temporary Schedule I basis become permanently scheduled upon enactment, removing the need for repeated renewals.
Rulemaking Flexibility: The Attorney General (head of the Department of Justice), working with the Secretary of Health and Human Services, can create rules to define the nitazene class more clearly for enforcement purposes, as long as they align with the chemical definition.
Research Exemption: Allows ongoing research on unscheduled nitazenes (as of enactment) to continue without immediate new registration requirements for up to 18 months, if it meets conditions like:
Being under an active Investigational New Drug (IND) application (FDA approval for testing new drugs) or similar exemption.
Prior approval by an Institutional Review Board (IRB, an ethics oversight group).
Notification to the Attorney General within 90 days.

Researchers must apply for proper registration during this period, with expedited processing to avoid disruptions. New research cannot start without compliance.

Significant Changes to Existing Law

Shifts from temporary, compound-by-compound scheduling (done by the Drug Enforcement Administration, or DEA) to a permanent, broad class-based approach under the CSA, which covers the entire family of nitazenes and preempts (blocks in advance) new designer variants.
Previously, the DEA could only temporarily schedule individual nitazenes for up to three years (renewable), requiring ongoing administrative action. This bill makes it permanent and proactive, simplifying updates to the law.

Potential Impacts

Government Agencies: Streamlines enforcement for the DEA and law enforcement by reducing the need for frequent temporary actions, allowing focus on prosecution and interdiction. The Department of Health and Human Services gains input on rules, supporting public health efforts.
Citizens: Could reduce overdose deaths by limiting nitazenes' availability in the illicit market, where they mix with other drugs like fentanyl and cause fatal poisonings due to their extreme potency (some are stronger than fentanyl). However, it may increase penalties for possession or use, affecting those struggling with addiction.
International Relations: No direct impacts mentioned, though it aligns with U.S. efforts to combat global synthetic opioid trafficking, potentially influencing cooperation with countries producing these substances.

Main Stakeholders Affected

Law Enforcement and Regulators: DEA, Attorney General's office, and local police benefit from clearer, broader authority to seize and prosecute nitazene-related activities.
Public Health Officials and Citizens: Those addressing the opioid crisis, including overdose victims, families, and addiction treatment providers, gain protection from these potent drugs entering the supply.
Researchers and Medical Community: Scientists studying opioids for potential medical uses (e.g., pain management) face temporary relief but must adapt to new registration rules to continue work.
Illicit Drug Producers and Users: Manufacturers and traffickers of nitazenes will encounter stricter federal bans and penalties, while users risk higher legal consequences without access to these substances.

Notable Legal, Constitutional, or Political Implications

Legal: Strengthens the CSA's framework for controlling "designer drugs" by using a class definition, which courts have upheld in similar cases (e.g., for fentanyl analogs). The research exemption balances enforcement with scientific needs, avoiding First Amendment challenges related to free inquiry.
Constitutional: Falls under Congress's authority to regulate interstate commerce (Article I, Section 8), as nitazenes cross state lines in the drug trade. No apparent conflicts with due process or equal protection.
Political: Introduced bipartisanship (by Reps. Vindman and Baumgartner), reflecting urgency in the ongoing opioid epidemic. It signals a proactive federal response to evolving drug threats without requiring annual appropriations, though future rulemaking could spark debates on overreach into chemical definitions.

This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.

Sponsor

Rep. Vindman, Eugene Simon [D-VA-7]

Cosponsors (4)

Rep. Baumgartner, Michael [R-WA-5], Rep. Onder, Robert F. [R-MO-3], Rep. Mackenzie, Ryan [R-PA-7], Rep. Neguse, Joe [D-CO-2]

Recent Actions

2025-08-22: Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
2025-08-22: Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
2025-08-22: Introduced in House
2025-08-22: Introduced in House

Bill Versions

Nitazene Control Act — issued 2025-08-22 — PDF (5 pages)